Skip to content
Doxazosin
Cardura (doxazosin) is a small molecule pharmaceutical. Doxazosin was first approved as Cardura on 1990-11-02. It is used to treat hypertension, prostatic hyperplasia, and urinary retention in the USA. The pharmaceutical is active against alpha-1A adrenergic receptor, alpha-1B adrenergic receptor, and alpha-1D adrenergic receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
cardiovascular diseasesD002318
Trade Name
FDA
EMA
Cardura (generic drugs available since 2000-10-18)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Doxazosin mesylate
Tradename
Company
Number
Date
Products
CARDURAViatrisN-019668 RX1990-11-02
4 products, RLD
CARDURA XLViatrisN-021269 RX2005-02-22
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
cardura New Drug Application2022-02-14
doxazosin mesylateANDA2023-06-09
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypertensionEFO_0000537D006973I10
prostatic hyperplasiaEFO_0000284D011470N40
urinary retentionHP_0000016D016055R33
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
C02: Antihypertensives
C02C: Antiadrenergic agents, peripherally acting
C02CA: Alpha-adrenoreceptor antagonists, peripherally acting
C02CA04: Doxazosin
HCPCS
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ApneaD001049HP_0002104R06.81112
HypoxiaD000860R09.0211
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Respiratory insufficiencyD012131HP_0002093J96.911
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AnesthesiaD000758112
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDOXAZOSIN
INNdoxazosin
Description
Doxazosin is a member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure. It has a role as an antihypertensive agent, an alpha-adrenergic antagonist, an antineoplastic agent, a vasodilator agent and an antihyperplasia drug. It is a member of quinazolines, a N-acylpiperazine, a N-arylpiperazine, a benzodioxine, a monocarboxylic acid amide and an aromatic amine.
Classification
Small molecule
Drug classantihypertensives (prazosin type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC
Identifiers
PDB
CAS-ID74191-85-8
RxCUI
ChEMBL IDCHEMBL707
ChEBI ID4708
PubChem CID3157
DrugBankDB00590
UNII IDNW1291F1W8 (ChemIDplus, GSRS)
Target
Agency Approved
ADRA1A
ADRA1A
ADRA1B
ADRA1B
ADRA1D
ADRA1D
Organism
Homo sapiens
Gene name
ADRA1A
Gene synonyms
ADRA1C
NCBI Gene ID
Protein name
alpha-1A adrenergic receptor
Protein synonyms
Alpha-1A adrenoceptor, Alpha-1A adrenoreceptor, Alpha-1C adrenergic receptor, Alpha-adrenergic receptor 1c, G protein coupled receptor
Uniprot ID
Mouse ortholog
Adra1a (11549)
alpha-1A adrenergic receptor (Q8BV77)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Cardura - Pfizer
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,711 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
33 adverse events reported
View more details